Alexandr N Chernov, Alexandr V Kim, Sofia S Skliar, Evgeniy V Fedorov, Anna N Tsapieva, Tatiana A Filatenkova, Aleksei L Chutko, Marina V Matsko, Elvira S Galimova, Olga V Shamova
OBJECTIVE: Glioblastoma multiforme (GBM) is the most aggressive and fatal malignant primary brain tumor. The enhancement of the survival rate for glioma patients remains limited, even with the utilization of a combined treatment approach involving surgery, radiotherapy, and chemotherapy. This study was designed to assess the expression of IDH1, TP53, EGFR, Ki-67, GFAP, H3K27M, MGMT, VEGF, NOS, CD99, and ATRX in glioblastoma tissue from 11 patients. We investigated the anticancer impact and combined effects of cathelicidin (LL-37), protegrin-1 (PG-1), with chemotherapy-temozolomide (TMZ), doxorubicin (DOX), carboplatin (CB), cisplatin (CPL), and etoposide (ETO) in primary GBM cells...
January 27, 2024: Cancer Chemotherapy and Pharmacology